Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression-Reference-Cited by-同舟云学术

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

Published:2023-10-05 Issue:14 Volume:389 Page:1298-1309
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Reif Andreas¹^ORCID,Bitter Istvan¹,Buyze Jozefien¹,Cebulla Kerstin¹,Frey Richard¹,Fu Dong-Jing¹,Ito Tetsuro¹^ORCID,Kambarov Yerkebulan¹,Llorca Pierre-Michel¹,Oliveira-Maia Albino J.¹^ORCID,Messer Thomas¹,Mulhern-Haughey Siobhán¹,Rive Benoît¹,von Holt Christian¹,Young Allan H.¹,Godinov Yordan¹

Affiliation:

1. From the Department of Psychiatry, Psychosomatic Medicine, and Psychotherapy, University Hospital, Goethe University Frankfurt, and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt (A.R.), Danuvius Klinik, Technische Universität München, Pfaffenhofen an der Ilm (T.M.), and Janssen Germany (K.C.) and Janssen EMEA (C.H.), Neuss — all in Germany; the Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary (I.B.); Janssen Pharmaceutica (J.B.) and...

Funder

Janssen EMEA

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2304145

Reference29 articles.

1. Towards achieving remission in the treatment of depression

2. Preventing Recurrent Depression: Long-Term Treatment for Major Depressive Disorder

3. Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report